{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-090892","form_type":"8-K","ticker":"BCLI","cik":"0001137883","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.225219+00:00","generated_at":"2026-06-11T10:09:04.432210+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BrainStorm Q2 net loss $5.3M; NurOwn ADCOM set for Sep 27, PDUFA Dec 8","bullets":["Net loss of $5.3M ($0.13 per share) vs $7.0M in Q2 2022.","Cash $0.75M at June 30; raised $7.5M in July direct offering.","FDA ADCOM for NurOwn BLA scheduled Sep 27; PDUFA target Dec 8, 2023.","Appointed Dr. Bob Dagher as Chief Development Officer and Dr. Kirk Taylor as Chief Medical Officer.","Biomarker data from Phase 3 showed NurOwn lowered neurofilament light, a predictor of clinical benefit in ALS."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-090892","json":"https://secwatch.observer/filing/0001104659-23-090892.json","markdown":"https://secwatch.observer/filing/0001104659-23-090892.md","text":"https://secwatch.observer/filing/0001104659-23-090892.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923090892/0001104659-23-090892-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923090892/tm2323640d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T10:09:04.432210+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f87dc74fed4221cb27eb3f80119e9e00919a38c2","claim":"BRAINSTORM CELL THERAPEUTICS INC. reported second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023 was approximately $5.3 million, EPS Net loss per share for the three months ended June 30, 2023 and 2022 was $0.13.","evidence_excerpt":"BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923090892/0001104659-23-090892-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss for the three months ended June 30, 2023 was approximately $5.3 million"},{"label":"EPS","value":"Net loss per share for the three months ended June 30, 2023 and 2022 was $0.13"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}